Nature Reviews Immunology Contents March 2018 Volume 18 Number 3 pp 149-219

If you are unable to see the message below, click here to view.
 

Advertisement
Quantitative analysis of neutrophil activation using Agilent Seahorse XF Technology Discover the benefits of measuring neutrophil activation using the XF analyzer! XF Technology provides a quantitative real-time assay for neutrophil activation. Tune in for examples of how this application can be used to examine neutrophil activation, and for a validated protocol. Watch the webinar to learn more
TABLE OF CONTENTS
March 2018 Volume 18 Number 3		Advertisement
2016 2-year Impact Factor 39.932 Journal Metrics 2-year Median 29	In this issue Research Highlights Focus on: Cancer immunotherapy Reviews Perspectives Correspondence   Also this month  Featured article: The diverse functions of the PD1 inhibitory pathway Arlene H. Sharpe & Kristen E. Pauken	Can you trust your Antibody? Implications for disease research. A recent publication in Scientific Reports rigorously tested nine commercially available antibodies for specificity and sensitivity and found that only one, from Cell Signaling Technology, met all validation criteria. Read this open-access article to explore the potentially serious implications of non-specific antibodies and disease research. Read more now.
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Poster on: CAR T cells in cancer therapy  Nature Reviews Drug Discovery present this Poster which provides an overview of the different ways to design and produce CAR T cells and the journey that has driven these CAR T cells to FDA approval in 2017.  Download free today Produced with support from:  Lonza Bioscience Solutions
Advertisement
Do you have a career question? The Naturejobs podcast features one-on-one Q&As, panel discussions and other exclusive content to help scientists with their careers. Hosted on the Naturejobs blog, the podcast is also available on iTunes and Soundcloud.  Listen today!
RESEARCH HIGHLIGHTS   Top Immunotherapy: Direct shot p149 | doi:10.1038/nri.2018.10 Intratumoural vaccination with immune-enhancing agents eradicates tumour metastases. PDF Infectious disease: γ δ T cells stop malarial comeback p150 | doi:10.1038/nri.2018.15 γ δ T cells stop malarial comeback T cells prevent the recurrence of malarial parasitaemia by producing M-CSF. PDF Immunotherapy: Cytokine boost for CAR T cells p150 | doi:10.1038/nri.2018.8 Chimeric antigen receptors that provide an antigen-dependent signal 3 to T cells have improved antitumour efficacy. PDF Tumour immunology: NK cells bring in the troops p151 | doi:10.1038/nri.2018.14 NK cells recruit cDC1s to the tumour microenviroment by producing the chemokines CCL5 and XCL1. PDF Microbiota: Pathobiont peacekeepers p152 | doi:10.1038/nri.2018.11 Pathobiont-specific peripherally derived regulatory T cells have an important role in maintaining gut homeostasis. PDF JOURNAL CLUB Altered self: the not-so-neo-antigens p152 | doi:10.1038/nri.2018.7 Jedd Wolchok describes a 1996 study by Alan Houghton and colleagues that showed how immune tolerance to self antigens on cancer cells could be overcome. PDF   Nature Reviews Immunology JOBS of the week Faculty Member � Cryo-EM St. Jude Children's Research Hospital (SJCRH) Postdoctoral Fellow Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Director / Senior Director, Immuno-Oncology Research Alector LLC Postdoctoral Fellow Position Available National Institutes of Health (NIH), Department of Health and Human Services (HHS) Postdoctoral Scientist (m / f) Cancer Immunology Boehringer Ingelheim More Science jobs from Nature Reviews Immunology EVENT Frontiers in Cancer Immunotherapy 26.04.18 New York, USA More science events from
Advertisement
Nature Outlook: Cancer immunotherapy  Drugs that mobilize our immune systems against cancer are dramatically improving care for many people, and research is rapidly moving ahead in the lab and the clinic.  Access this Outlook free >> Produced with support from  F. Hoffmann-La Roche Ltd   Medimmune  Produced with support of a grant from Merck & Co., Inc.
Focus on: Cancer immunotherapy REVIEWS Top The diverse functions of the PD1 inhibitory pathway Arlene H. Sharpe & Kristen E. Pauken p153 | doi:10.1038/nri.2017.108 In this Review, the authors detail the complex expression patterns and regulation of programmed cell death protein 1 (PD1) and its ligands. The authors focus on the importance of understanding these pathways in order to optimize the efficiency and safety of immune checkpoint blockade in patients. Abstract | Full Text | PDF   Towards personalized, tumour-specific, therapeutic vaccines for cancer Zhuting Hu, Patrick A. Ott & Catherine J. Wu p168 | doi:10.1038/nri.2017.131 Recent studies showing that neoantigens are crucial targets of the antitumour immune response have supported the progression of personalized cancer vaccines to clinical trials. Abstract | Full Text | PDF   The dawn of vaccines for cancer prevention Olivera J. Finn p183 | doi:10.1038/nri.2017.140 Heeding the adage “prevention is better than cure”, Olivera J. Finn proposes that vaccinating individuals who have pre-malignant lesions gives the immune system the upper hand and can prevent progression to cancer. Abstract | Full Text | PDF
Advertisement
Online-only and open access, npj Primary Care Respiratory Medicine is the only fully-indexed scientific journal devoted to the management of respiratory diseases in primary care.   Explore the benefits of submitting your next research article.
Focus on: Cancer immunotherapy PERSPECTIVES Top OPINION Improving immune–vascular crosstalk for cancer immunotherapy Yuhui Huang, Betty Y. S. Kim, Charles K. Chan, Stephen M. Hahn, Irving L. Weissman & Wen Jiang p195 | doi:10.1038/nri.2017.145 Normalization of the tumour vasculature can improve immune effector cell infiltration, leading to immunotherapy potentiation. In this Opinion article, Huang et al. propose that reciprocal regulation between tumour vascular normalization and immune reprogramming forms a positive feedback loop that can induce durable antitumour immunity within the tumour microenvironment. Abstract | Full Text | PDF   OPINION The tumour glyco-code as a novel immune checkpoint for immunotherapy Ernesto RodrIguez, Sjoerd T. T. Schetters & Yvette van Kooyk p204 | doi:10.1038/nri.2018.3 Could the specific glycosylation signatures associated with tumour cells be harnessed for immunotherapy purposes? In this Opinion, the authors propose that the tumour glyco-code may represent a novel immune checkpoint that could be targeted in the clinic. Abstract | Full Text | PDF | Supplementary information   OPINION Synthetic immune niches for cancer immunotherapy Jorieke Weiden, Jurjen Tel & Carl G. Figdor p212 | doi:10.1038/nri.2017.89 Carl Figdor and colleagues propose that delivering cancer immunotherapy in the context of engineered three-dimensional scaffolds may boost anticancer immunity. The synthetic scaffolds, which can be linked to immunomodulatory factors, can act as immune niches to support the priming and maintenance of antitumour immune responses. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Foreign antigen-independent memory-phenotype CD4+ T cells: a new player in innate immunity? Takeshi Kawabe, Jinfang Zhu & Alan Sher p219 | doi:10.1038/nri.2018.12 Full Text | PDF
REPLY		Top
Foreign antigen-independent memory-phenotype CD4+ T cells: a new player in innate immunity? Ross M. Kedl & Jason T. White p219 | doi:10.1038/nri.2018.13 Full Text | PDF
Erratum: Regulation of T cell signalling by membrane lipids Wei Wu, Xiaoshan Shi & Chenqi Xu p219 | doi:10.1038/nri.2018.9 Full Text | PDF
Advertisement
npj Vaccines is an online-only, open access, multidisciplinary journal dedicated to publishing cutting-edge research and development on human and veterinary vaccines. npj Vaccines is now open for submissions.   Explore the benefits of submitting your next manuscript to the journal.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.